Well-Funded Atreca Looks to Take the Breaks Off Cancer Treatments

Interviewer:
Tom Salemi
Content Director
Healthegy

Interviewee:
Tito A Serafini, PhD, CEO / CSO, CEO, President, Chief Scientfic Officer
Atreca Inc.

Privately held Atreca is developing novel therapeutics using its Immune Repertoire Capture technology to profile a patient’s immune response at the single-cell level at very high throughput without bias or error, enabling the identification and generation of functional human antibodies and T Cell Receptors without prior knowledge of antigen. The company secured a $54 million Series A at the end of 2016 and counts the Gates Foundation among its investors.

Tito Serafini is president, CEO, chief scientific officer, and co-founder of Atreca. Before founding Atreca, he was chief scientific officer of Nuon Therapeutics, a development-stage biotechnology company. He also was a co-founder of Renovis, a public biotechnology company, where he served as an executive officer in multiple technical and business management roles, including leading the research and M&A functions.

To hear from more medtech leaders register for the Medtech Conference
http://medtechconference.com/

Interview Index:
:058 – What is the origin of the company?
1:41 – What was appealing about the Immune Repertoire Capture technology?
3:24 – How did the company secure capital from the Gates Foundation?
5:16 – How does the Gates Foundation function as an investor?
6:16 – Was Atreca always steering toward immuno-oncology as a focus?
7:36 – Can you dissect the rising interest in immuno-oncology markets?
8:07 – “If you speak to oncologists they are giddy.”
10:51 – What parts of your pipeline will advance the fastest?

source